|
Oct 16
|
Acticor Biotech: Extension of the Call for Tenders With a View to a Restructuring Plan or Sale Under the Receivership Procedure
|
|
Oct 14
|
Acticor Biotech appoints François Guillet as Chief Financial Officer
|
|
Oct 11
|
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
|
|
Jul 26
|
Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the GREEN Study
|
|
May 27
|
Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024
|
|
Oct 4
|
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of September 30, 2023
|